Loading...
Currently, two regimens for the treatment of hepatitis C virus (HCV) infection seem safe and effective in patients requiring hemodialysis: grazoprevir/elbasvir and paritaprevir/ritonavir/ombitasvir/dasabuvir. Although, sofosbuvir is a cornerstone of many HCV treatment regimens, its use is not typically recommended in patients with severe renal impairment (glomerular filtration rates <30 mL/min).
In a multicenter, prospective, observational study, investigators assessed the safety and efficacy of sofosbuvir 400 mg daily or 3 times a week with daclatasvir, ledipasvir, ribavirin, or simeprevir in HCV-infected patients on hemodialysis. Drug plasma concentrations of sofosbuvir were determined 4 hours before and after hemodialysis and 1.5 hours af…